Aytu BioPharma Inc (AYTU): Price-to-Sales Ratio

Corporate company logo of Aytu BioPharma, Inc. (AYTU)

Aytu BioPharma, Inc. (AYTU) is expanding sales of pediatric ADHD medications and reducing logistics costs. P/S fluctuations confirm the business valuation trend, where the value 0.30 represents the current metric. Resilience is driven by the diversification of drug distribution rights. Personnel stability is maintained through the targeted hiring of specialized managers and compliance experts.

AYTU: aytubio.com P/S Multiple 07/04/2022 - 11/14/2026

Metric breakdowns and analytics for Aytu BioPharma, Inc. (AYTU)

- share price and consensus valuation forecast:
Price Performance Chart aytubio.com|AYTU - Price Target Chart
- stock exchange capitalization data:
Market Valuation Aytu Therapeutics|AYTU - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value of a Share Aytu BioPharma|AYTU - Book Capitalization|Market Capitalization to Book Value Ratio aytubio.com|AYTU - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Aytu BioPharma, Inc.|AYTU - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio aytubio.com|AYTU - Company Aggregate Debts|Debts to Book Capitalization Aytu Therapeutics|AYTU - Company Long-Term Debts|Company Short-Term Debts Aytu BioPharma|Immediate Liquidity aytubio.com
- earnings and valuation multiples information:
AYTU - Net Income|Future Net Profit Aytu BioPharma, Inc.|AYTU - Price to Earnings Ratio|Forward P/E Multiple aytubio.com|AYTU - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Aytu Therapeutics|AYTU - Operating profit EBITDA|Earnings per share for the last twelve months Aytu BioPharma|AYTU - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months aytubio.com|AYTU - Earnings per share growth in current year|Expected net earnings per share growth next year Aytu BioPharma, Inc.
- issuer revenue and sales details:
AYTU - Company Revenue|Company Expected Revenue aytubio.com|AYTU - P/S Multiple|Forward Price to Sales Aytu Therapeutics
General company analysis:AYTU Aytu BioPharma Inc
Finished products of Aytu BioPharma

Aytu BioPharma's specialization in pediatric ADHD medications generates a steady revenue stream. This cash flow serves as the basis for calculating the P/S ratio, which compares the business's market value to its annual turnover. This metric determines how much an investor pays per unit of sales, revealing whether the asset is overvalued or undervalued. Analyzing the current P/S level allows for an assessment of the capitalization's resilience to market volatility.

Competing companies

VRTX (vrtx.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alnylam ALNY|INSM (Insmed Inc.) - Price-to-Sales Ratio|United Therapeutics Corp. - P/S Multiple|Market Capitalization-to-Revenue Ratio BMRN (BioMarin Corp)|BBIO: P/S Multiple|BGM Group (BGM) - P/S Multiple|Price-to-Revenue Ratio Cogent Biosciences, Inc.|XERS: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Keros Pharma (KROS)|Market Cap to Revenue Arcturus Corp ARCT|P/S Multiple ETON (Eton Pharmaceuticals)|P/S Multiple kamada.com KMDA|Fulcrum Therapeutics, Inc. - P/S Multiple|ABEO - P/S Multiple|MREO (mereobiopharma.com) - Market Cap to Revenue|Price to Sales Protalix BioTherapeutics, Inc (PLX)|Market Cap to Revenue PLRX|APLT (appliedtherapeutics.com) - Market Cap to Sales Volume|Market Cap to Revenue RNTX (Rein Therapeutics)|P/S Multiple gelteq.com (GELS)|Chemomab Therapeutics Ltd. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio SRXH|Polyrizon Ltd. - P/S Multiple|AEZS: Price-to-Revenue Ratio|CYTH: P/S Multiple|INZY - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Reneo Pharma|Price to Sales COSCIENS Bio CSCI